Eliem Therapeutics, Inc.
23515 NE Novelty Hill Road, Suite B221 #125
Redmond, WA 98053
August 5, 2021
Via EDGAR Submission
Securities and Exchange Commission
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Sasha Parish |
| Vanessa Robertson |
| Dillon Hagius |
| Jeffrey Gabor |
| Re: | Eliem Therapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333-257980) Withdrawal of Request for Acceleration of Effective Date |
Ladies and Gentlemen:
Reference is made to the several letters, each filed as correspondence via EDGAR on August 3, 2021, in which both we and the several underwriters requested the acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-257980) for August 5, 2021, at 4:00 p.m. Eastern Time, or as soon thereafter as practicable, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such registration statement be declared effective at this time and we hereby formally withdraw both our and the underwriters’ requests for acceleration of the effective date.
| Very truly yours, | ||
| Eliem Therapeutics, Inc. | ||
| /s/ Robert W. Azelby | ||
| By: | Robert W. Azelby | |
| Title: | Chief Executive Officer | |
| cc: | Alan Hambelton, Cooley LLP |
| Julia Stark, Cooley LLP |
| Brian Cuneo, Latham & Watkins LLP |
| Phillip Stoup, Latham & Watkins LLP |